Cargando…
Current knowledge, challenges and innovations in developmental pharmacology: A combined conect4children Expert Group and European Society for Developmental, Perinatal and Paediatric Pharmacology White Paper
Developmental pharmacology describes the impact of maturation on drug disposition (pharmacokinetics, PK) and drug effects (pharmacodynamics, PD) throughout the paediatric age range. This paper, written by a multidisciplinary group of experts, summarizes current knowledge, and provides suggestions to...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9787161/ https://www.ncbi.nlm.nih.gov/pubmed/34180088 http://dx.doi.org/10.1111/bcp.14958 |
_version_ | 1784858450839207936 |
---|---|
author | Smits, Anne Annaert, Pieter Cavallaro, Giacomo De Cock, Pieter A. J. G. de Wildt, Saskia N. Kindblom, Jenny M. Lagler, Florian B. Moreno, Carmen Pokorna, Paula Schreuder, Michiel F. Standing, Joseph F. Turner, Mark A. Vitiello, Benedetto Zhao, Wei Weingberg, Annelie‐Martina Willmann, Raffaella van den Anker, John Allegaert, Karel |
author_facet | Smits, Anne Annaert, Pieter Cavallaro, Giacomo De Cock, Pieter A. J. G. de Wildt, Saskia N. Kindblom, Jenny M. Lagler, Florian B. Moreno, Carmen Pokorna, Paula Schreuder, Michiel F. Standing, Joseph F. Turner, Mark A. Vitiello, Benedetto Zhao, Wei Weingberg, Annelie‐Martina Willmann, Raffaella van den Anker, John Allegaert, Karel |
author_sort | Smits, Anne |
collection | PubMed |
description | Developmental pharmacology describes the impact of maturation on drug disposition (pharmacokinetics, PK) and drug effects (pharmacodynamics, PD) throughout the paediatric age range. This paper, written by a multidisciplinary group of experts, summarizes current knowledge, and provides suggestions to pharmaceutical companies, regulatory agencies and academicians on how to incorporate the latest knowledge regarding developmental pharmacology and innovative techniques into neonatal and paediatric drug development. Biological aspects of drug absorption, distribution, metabolism and excretion throughout development are summarized. Although this area made enormous progress during the last two decades, remaining knowledge gaps were identified. Minimal risk and burden designs allow for optimally informative but minimally invasive PK sampling, while concomitant profiling of drug metabolites may provide additional insight in the unique PK behaviour in children. Furthermore, developmental PD needs to be considered during drug development, which is illustrated by disease‐ and/or target organ‐specific examples. Identifying and testing PD targets and effects in special populations, and application of age‐ and/or population‐specific assessment tools are discussed. Drug development plans also need to incorporate innovative techniques such as preclinical models to study therapeutic strategies, and shift from sequential enrolment of subgroups, to more rational designs. To stimulate appropriate research plans, illustrations of specific PK/PD‐related as well as drug safety‐related challenges during drug development are provided. The suggestions made in this joint paper of the Innovative Medicines Initiative conect4children Expert group on Developmental Pharmacology and the European Society for Developmental, Perinatal and Paediatric Pharmacology, should facilitate all those involved in drug development. |
format | Online Article Text |
id | pubmed-9787161 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97871612022-12-27 Current knowledge, challenges and innovations in developmental pharmacology: A combined conect4children Expert Group and European Society for Developmental, Perinatal and Paediatric Pharmacology White Paper Smits, Anne Annaert, Pieter Cavallaro, Giacomo De Cock, Pieter A. J. G. de Wildt, Saskia N. Kindblom, Jenny M. Lagler, Florian B. Moreno, Carmen Pokorna, Paula Schreuder, Michiel F. Standing, Joseph F. Turner, Mark A. Vitiello, Benedetto Zhao, Wei Weingberg, Annelie‐Martina Willmann, Raffaella van den Anker, John Allegaert, Karel Br J Clin Pharmacol Article Developmental pharmacology describes the impact of maturation on drug disposition (pharmacokinetics, PK) and drug effects (pharmacodynamics, PD) throughout the paediatric age range. This paper, written by a multidisciplinary group of experts, summarizes current knowledge, and provides suggestions to pharmaceutical companies, regulatory agencies and academicians on how to incorporate the latest knowledge regarding developmental pharmacology and innovative techniques into neonatal and paediatric drug development. Biological aspects of drug absorption, distribution, metabolism and excretion throughout development are summarized. Although this area made enormous progress during the last two decades, remaining knowledge gaps were identified. Minimal risk and burden designs allow for optimally informative but minimally invasive PK sampling, while concomitant profiling of drug metabolites may provide additional insight in the unique PK behaviour in children. Furthermore, developmental PD needs to be considered during drug development, which is illustrated by disease‐ and/or target organ‐specific examples. Identifying and testing PD targets and effects in special populations, and application of age‐ and/or population‐specific assessment tools are discussed. Drug development plans also need to incorporate innovative techniques such as preclinical models to study therapeutic strategies, and shift from sequential enrolment of subgroups, to more rational designs. To stimulate appropriate research plans, illustrations of specific PK/PD‐related as well as drug safety‐related challenges during drug development are provided. The suggestions made in this joint paper of the Innovative Medicines Initiative conect4children Expert group on Developmental Pharmacology and the European Society for Developmental, Perinatal and Paediatric Pharmacology, should facilitate all those involved in drug development. John Wiley and Sons Inc. 2021-07-23 2022-12 /pmc/articles/PMC9787161/ /pubmed/34180088 http://dx.doi.org/10.1111/bcp.14958 Text en © 2021 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Article Smits, Anne Annaert, Pieter Cavallaro, Giacomo De Cock, Pieter A. J. G. de Wildt, Saskia N. Kindblom, Jenny M. Lagler, Florian B. Moreno, Carmen Pokorna, Paula Schreuder, Michiel F. Standing, Joseph F. Turner, Mark A. Vitiello, Benedetto Zhao, Wei Weingberg, Annelie‐Martina Willmann, Raffaella van den Anker, John Allegaert, Karel Current knowledge, challenges and innovations in developmental pharmacology: A combined conect4children Expert Group and European Society for Developmental, Perinatal and Paediatric Pharmacology White Paper |
title | Current knowledge, challenges and innovations in developmental pharmacology: A combined conect4children Expert Group and European Society for Developmental, Perinatal and Paediatric Pharmacology White Paper |
title_full | Current knowledge, challenges and innovations in developmental pharmacology: A combined conect4children Expert Group and European Society for Developmental, Perinatal and Paediatric Pharmacology White Paper |
title_fullStr | Current knowledge, challenges and innovations in developmental pharmacology: A combined conect4children Expert Group and European Society for Developmental, Perinatal and Paediatric Pharmacology White Paper |
title_full_unstemmed | Current knowledge, challenges and innovations in developmental pharmacology: A combined conect4children Expert Group and European Society for Developmental, Perinatal and Paediatric Pharmacology White Paper |
title_short | Current knowledge, challenges and innovations in developmental pharmacology: A combined conect4children Expert Group and European Society for Developmental, Perinatal and Paediatric Pharmacology White Paper |
title_sort | current knowledge, challenges and innovations in developmental pharmacology: a combined conect4children expert group and european society for developmental, perinatal and paediatric pharmacology white paper |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9787161/ https://www.ncbi.nlm.nih.gov/pubmed/34180088 http://dx.doi.org/10.1111/bcp.14958 |
work_keys_str_mv | AT smitsanne currentknowledgechallengesandinnovationsindevelopmentalpharmacologyacombinedconect4childrenexpertgroupandeuropeansocietyfordevelopmentalperinatalandpaediatricpharmacologywhitepaper AT annaertpieter currentknowledgechallengesandinnovationsindevelopmentalpharmacologyacombinedconect4childrenexpertgroupandeuropeansocietyfordevelopmentalperinatalandpaediatricpharmacologywhitepaper AT cavallarogiacomo currentknowledgechallengesandinnovationsindevelopmentalpharmacologyacombinedconect4childrenexpertgroupandeuropeansocietyfordevelopmentalperinatalandpaediatricpharmacologywhitepaper AT decockpieterajg currentknowledgechallengesandinnovationsindevelopmentalpharmacologyacombinedconect4childrenexpertgroupandeuropeansocietyfordevelopmentalperinatalandpaediatricpharmacologywhitepaper AT dewildtsaskian currentknowledgechallengesandinnovationsindevelopmentalpharmacologyacombinedconect4childrenexpertgroupandeuropeansocietyfordevelopmentalperinatalandpaediatricpharmacologywhitepaper AT kindblomjennym currentknowledgechallengesandinnovationsindevelopmentalpharmacologyacombinedconect4childrenexpertgroupandeuropeansocietyfordevelopmentalperinatalandpaediatricpharmacologywhitepaper AT laglerflorianb currentknowledgechallengesandinnovationsindevelopmentalpharmacologyacombinedconect4childrenexpertgroupandeuropeansocietyfordevelopmentalperinatalandpaediatricpharmacologywhitepaper AT morenocarmen currentknowledgechallengesandinnovationsindevelopmentalpharmacologyacombinedconect4childrenexpertgroupandeuropeansocietyfordevelopmentalperinatalandpaediatricpharmacologywhitepaper AT pokornapaula currentknowledgechallengesandinnovationsindevelopmentalpharmacologyacombinedconect4childrenexpertgroupandeuropeansocietyfordevelopmentalperinatalandpaediatricpharmacologywhitepaper AT schreudermichielf currentknowledgechallengesandinnovationsindevelopmentalpharmacologyacombinedconect4childrenexpertgroupandeuropeansocietyfordevelopmentalperinatalandpaediatricpharmacologywhitepaper AT standingjosephf currentknowledgechallengesandinnovationsindevelopmentalpharmacologyacombinedconect4childrenexpertgroupandeuropeansocietyfordevelopmentalperinatalandpaediatricpharmacologywhitepaper AT turnermarka currentknowledgechallengesandinnovationsindevelopmentalpharmacologyacombinedconect4childrenexpertgroupandeuropeansocietyfordevelopmentalperinatalandpaediatricpharmacologywhitepaper AT vitiellobenedetto currentknowledgechallengesandinnovationsindevelopmentalpharmacologyacombinedconect4childrenexpertgroupandeuropeansocietyfordevelopmentalperinatalandpaediatricpharmacologywhitepaper AT zhaowei currentknowledgechallengesandinnovationsindevelopmentalpharmacologyacombinedconect4childrenexpertgroupandeuropeansocietyfordevelopmentalperinatalandpaediatricpharmacologywhitepaper AT weingberganneliemartina currentknowledgechallengesandinnovationsindevelopmentalpharmacologyacombinedconect4childrenexpertgroupandeuropeansocietyfordevelopmentalperinatalandpaediatricpharmacologywhitepaper AT willmannraffaella currentknowledgechallengesandinnovationsindevelopmentalpharmacologyacombinedconect4childrenexpertgroupandeuropeansocietyfordevelopmentalperinatalandpaediatricpharmacologywhitepaper AT vandenankerjohn currentknowledgechallengesandinnovationsindevelopmentalpharmacologyacombinedconect4childrenexpertgroupandeuropeansocietyfordevelopmentalperinatalandpaediatricpharmacologywhitepaper AT allegaertkarel currentknowledgechallengesandinnovationsindevelopmentalpharmacologyacombinedconect4childrenexpertgroupandeuropeansocietyfordevelopmentalperinatalandpaediatricpharmacologywhitepaper |